Apellis Pharmaceuticals, Inc.
APLS
$22.00
$0.753.53%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 458.58M | 178.49M | 166.80M | 212.53M | 196.83M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 458.58M | 178.49M | 166.80M | 212.53M | 196.83M |
| Cost of Revenue | 92.72M | 80.64M | 120.78M | 117.21M | 122.13M |
| Gross Profit | 365.86M | 97.85M | 46.02M | 95.32M | 74.70M |
| SG&A Expenses | 142.68M | 131.14M | 129.35M | 121.48M | 121.98M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 235.40M | 211.78M | 250.13M | 238.69M | 244.11M |
| Operating Income | 223.18M | -33.29M | -83.33M | -26.16M | -47.28M |
| Income Before Tax | 216.32M | -41.69M | -91.88M | -36.07M | -56.85M |
| Income Tax Expenses | 602.00K | 466.00K | 341.00K | 286.00K | 592.00K |
| Earnings from Continuing Operations | 215.72M | -42.15M | -92.23M | -36.35M | -57.45M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 215.72M | -42.15M | -92.23M | -36.35M | -57.45M |
| EBIT | 223.18M | -33.29M | -83.33M | -26.16M | -47.28M |
| EBITDA | 223.52M | -32.84M | -82.88M | -25.72M | -46.82M |
| EPS Basic | 1.71 | -0.33 | -0.74 | -0.29 | -0.46 |
| Normalized Basic EPS | 1.07 | -0.21 | -0.46 | -0.18 | -0.29 |
| EPS Diluted | 1.67 | -0.33 | -0.74 | -0.29 | -0.46 |
| Normalized Diluted EPS | 1.04 | -0.21 | -0.46 | -0.18 | -0.29 |
| Average Basic Shares Outstanding | 126.42M | 126.02M | 125.45M | 124.52M | 124.23M |
| Average Diluted Shares Outstanding | 130.07M | 126.02M | 125.45M | 124.52M | 124.23M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |